Leading Gastroenterologists to Discuss Current and Future Applications for Capsule Endoscopy at Third Annual International Conference on Capsule Endoscopy

Four-day program includes sessions on latest advances in diagnosis of Crohn's disease, detection of small bowel tumors, pediatric applications and other small bowel disorders

YOQNEAM, Israel, February 26, 2004 -- Given Imaging Ltd. (Nasdaq: GIVN) announced today that leading gastroenterologists from around the world will meet to discuss the latest advances in and applications for Capsule Endoscopy at the Third Annual International Conference on Capsule Endoscopy (ICCE) in Miami, FL from February 29th - March 3rd. Over 90 abstracts and posters will be presented to a gathering of more than 250 physicians from 30 countries around the world.

“The ICCE has become an essential event for those interested in Video Capsule Endoscopy and its evolving impact on the practice of gastroenterology. This year's meeting promises to be the most exciting to date as new data is reported on the capsule's role in the diagnosis and management of patients with small bowel disorders,” said Dr. David Cave, Chief of the St. Elizabeth's GI Division. “Data and insights regarding promising future applications will also be presented and discussed for the first time, such as the use of Video Capsule Endoscopy for patients who present in the emergency room with acute gastrointestinal bleeding and a new capsule designed to detect esophageal disorders.”

Scientific sessions will focus on the early diagnosis of Inflammatory Bowel Disease and small bowel tumors, new developments in managing gastrointestinal bleeding, comparisons of Capsule Endoscopy versus alternative modalities, Capsule Endoscopy in the pediatric population and the use of Capsule Endoscopy to detect NSAID-related damage among other topics.

Keynote lectures topics include:

• Clinical outcome of patients with obscure gastrointestinal bleeding after Capsule Endoscopy: report of 100 consecutive cases
• Celiac Disease: The Emerging Role of Capsule Endoscopy
• Crohn's Disease: Capsule Endoscopy vs. Comparative modalities for diagnosis of early stage Crohn's disease
• Meta-analysis of Capsule Endoscopy vs. alternative modalities in 24 studies and 530 patients
• Esophageal Capsule Endoscopy (ECE) compared to traditional endoscopy for the evaluation of patients with GERD symptoms.

A full agenda for the ICCE is available by visiting www.givenimaging.com.

Post-ICCE Conference Webcast Information
Given Imaging will host a conference call with three leading gastroenterologists to review consensus findings from the Third Annual ICCE on Wednesday, March 3rd at 1:30 pm ET. The conference call will be webcast through the Company's website www.givenimaging.com. Specific details on the call will be released next week.

About Given Imaging
Given Imaging develops, produces and markets the Given® Diagnostic System featuring the M2A® Capsule Endoscope, the only method for direct visualization of the entire small intestine that is naturally ingested. The system uses a disposable miniature video camera contained in a capsule which is ingested by the patient. The M2A® Capsule passes naturally through the digestive tract, transmitting high quality color images, without interfering with the patient's normal activities. The system received clearance from the FDA in August 2001 and received permission to affix the CE mark in May 2001. Distribution channels for the system have been established in more than 50 countries worldwide. More than 80,000 capsules have been used in clinical practice. Thousands of patients around the world have benefited from the M2A® Capsule which has been used to diagnose a range of diseases of the small intestine including Crohn's Disease, Celiac disease and other malabsorption disorders, benign and malignant tumors of the small intestine, vascular disorders, medication related small bowel injury, as well as a range of pediatric small bowel disorders. For more information, visit www.givenimaging.com.

This press release contains forward-looking statements about Given Imaging, including projections about our business, our future revenues, and our future profitability, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, statements in the future tense, words such as "anticipates," "estimates," "expects," "intends," "plans," "believes," and words and terms of similar substance used in connection with any discussion of future operating or financial performance identify such forward-looking statements. Those forward-looking statements are not guarantees of future performance and actual results could differ materially from our current expectations as a result of numerous factors, including but not limited to the following: changes in regulatory environment, our success in implementing our sales, marketing and manufacturing plan, protection and validity of patents and other intellectual property rights, the impact of currency exchange rates, the effect of competition by other companies, the outcome of future litigation, the reimbursement policies for our product from healthcare payors, quarterly variations in operating results, the possibility of armed conflict or civil or military unrest in Israel and other risks disclosed in our filings with the U.S. Securities Exchange Commission.

19.May'04